PYPD (polypid.com) רווח נקי למניה (EPS TTM)

PolyPid Ltd. maintains a stable output of antibacterial agents through its own automated plants in Israel. The 12-month EPS trend captures this driver, where -1.47 reflects the latest metric level. The development of unique local drug delivery systems reduces postoperative risks, while future pricing power relies on patents in the field of sustained-release antibiotics.

Investors are assessing the resilience of PolyPid Ltd. (PYPD) through the dynamics of real earnings per share. This metric is calculated as the ratio of total annual net income to the number of shares outstanding. By analyzing the current level of annual net income per share, one can determine the monetization efficiency of the PLEXEL platform. Growth in this indicator confirms the commercial success of the closed-loop therapy, while a downward trend signals risks of capital loss.